First AD

Second AD

CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer

Video content above is prompted by the following:

How do you use adjuvant therapy in patients with HR+/HER2- early-stage breast cancer (eBC)?

How do risk factors impact your adjuvant treatment strategy?

Which risk factors are most influential, and why?

Please briefly mention adjuvant CDK4/6i studies in eBC

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Updates in the Treatment of HR+/HER2- Breast Cancer  

Peer Exchange

Panelists discuss how adjuvant therapy in HR+/HER2- early-stage breast cancer is influenced by key risk factors, with a focus on recent studies involving CDK4/6 inhibitors like abemaciclib, ribociclib, and palbociclib, and how these treatments are shaping the adjuvant treatment strategy based on efficacy data from trials such as MonarchE, NATALEE, and PALLAS.
